Home / Stocks / BIOVF

Swedish Orphan Biovitrum AB (publ) (BIOVF, Biotechnology) Stock Valuation & Fair Value Quality business with a solid forward outlook

Swedish Orphan Biovitrum AB (publ) (BIOVF, Biotechnology) trades at a blended P/E of 32.2, about 36% below its historical normal valuation, with a forward growth estimate of 34.5% and a PEG of 0.93. Analysts' one-year estimates have been hit 27% of the time.

DATA AS OF 2026-09-21
Blended P/E
32.2
Normal P/E
50.2
PEG
0.93
Fwd growth
34.5%
Div yield
0.0%
RSI (14)
30.0
Neutral

Valuation flags

Verdict history

tickerseer's rating has been quality business with a solid forward outlook since 2026-09-19.

Blended P/E and rating by weekBlended P/E moved from 32.2 to 32.2 between 2026-09-19 and 2026-09-21, against a normal P/E of 50.2, with 0 rating changes over 2 recorded weeks.2026-09-19: P/E 32.2, Quality business with a solid forward outlook (recalculated)2026-09-21: P/E 32.2, Quality business with a solid forward outlook35.040.045.050.0Sep 19Sep 20Sep 21Normal P/E 50.2
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Ratings recorded live since 2026-09-21. Earlier points apply today's valuation rules to the metrics tickerseer archived that week.

WeekBlended P/EPremium to normal P/ERating
2026-09-19P/E 32.2-36%Quality business with a solid forward outlook
2026-09-21P/E 32.2-36%Quality business with a solid forward outlook ← now

Frequently asked questions

Is Swedish Orphan Biovitrum AB (publ) stock overvalued?

At a blended P/E of 32.2 versus its historical normal P/E of 50.2, Swedish Orphan Biovitrum AB (publ) trades about 36% below its typical valuation, with a PEG of 0.93 on 34.5% forward growth. tickerseer currently rates it quality business with a solid forward outlook.

What is Swedish Orphan Biovitrum AB (publ)'s fair value and PEG?

Swedish Orphan Biovitrum AB (publ) trades at a blended P/E of 32.2 against a historical normal P/E of 50.2, a PEG of 0.93, and a forward growth estimate of 34.5%.

Has tickerseer's rating of Swedish Orphan Biovitrum AB (publ) changed?

tickerseer's rating has been quality business with a solid forward outlook since 2026-09-19.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track BIOVF free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.